Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Circulation

Volumn 124, Issue 5, 2011, Pages 544-554

  Mahaffey, Kenneth W ^a   Wojdyla, Daniel M ^a   Carroll, Kevin ^b   Becker, Richard C ^a   Storey, Robert F ^c   Angiolillo, Dominick J ^d   Held, Claes ^e   Cannon, Christopher P ^f   James, Stefan ^e   Pieper, Karen S ^a   Horrow, Jay ^b   Harrington, Robert A ^a   Wallentinon, Lars ^e  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Aspirin; Myocardial infarction; Outcomes

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BIOGEOGRAPHIC REGION; BLEEDING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE DRUG DOSE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; UNITED STATES;

ADENOSINE; AGED; ASPIRIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; STROKE; TICLOPIDINE; UNITED STATES; WORLD HEALTH;

EID: 80051550924     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.047498     Document Type: Article

References (20)

1. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design and baseline characteristics of the PLATelet inhibition and Outcomes (PLATO) trial. Am Heart J. 2009;157:599-605
2. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes [supplement]. N Engl J Med. 2009;361:1045-1057, e1-e34. http://www.nejm.org/doi/ suppl/10.1056/NEJMoa0904327/suppl-file/nejm-wallentin-1045sa1.pdf. Accessed June 10, 2011.
4. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-2945.
5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-e304.
6. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851. (Pubitemid 350007959)
7. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation. 1995;91:1659-1668.
8. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation. 2000;101:2557-2567. (Pubitemid 30350632)
9. Fox KA, Goodman S, Bigonzi F, Le Louer V, Cohen M. Inter-regional differences and outcome in unstable angina. Eur Heart J. 2000;21: 1433-1439.
10. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688. (Pubitemid 13160815)
11. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007;5:577-582. (Pubitemid 46680692)
12. Storey RF, Angiolillo D, Patil S, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon C, Becker R, Wallentin L. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO PLATELET substudy. J Am Coll Cardiol. 2010;56:1456-1462.
13. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925-934.
14. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost. 2010;8:613-615.
15. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011;9:552-561.
16. Warner TD, Nylander S, Whatling C. Antiplatelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual antiplatelet therapy [published ahead of print February 15, 2011]. Br J Clin Pharmacol. doi:10.1111/j.1365-2125.2011.03943.x.
17. CURRENT-OASIS 7 Investigators, Mehta S, Bassand J, Chrolavicius S, Diaz R, Eikelboom J, Fox K, Granger C, Jolly S, Joyner C, Rupprecht H, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363: 930-942.
18. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernpández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660. (Pubitemid 47227122)
19. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Jacobs AK. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:1920-1959.
20. Pieper KS, Tsiatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang WC, Griffin J, Armstrong PW, Califf RM, Harrington RA. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes; exploration of methods. Circulation. 2004;109: 641-646. (Pubitemid 38198872)